Biogen opts into Denali Alzheimer's program targeting amyloid beta plaque
Biogen is taking another step in its neurodegenerative disease collaboration with Denali Therapeutics.
The big biotech announced Wednesday it is picking up an option for a preclinical Alzheimer’s program from Denali, taking over all development activities and costs. In exchange, Denali gets some cash — for an undisclosed amount — and the promise of some milestones down the road.
Biogen and Denali spokespeople both declined to provide specific financial details for the option payment and milestones. Additionally, neither company disclosed this option’s financials when they signed the collaboration in August 2020.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.